A61K 31/625
Having heterocyclic substituents
Official title: having heterocyclic substituents, e.g. 4-salicycloylmorpholine, (sulfasalazine A61K31/635)
A61K31/625 (Having heterocyclic substituents) appears on 40 US grants and 59 published applications in this corpus.
Search patents in A61K- Granted patents
- 40
- Published applications
- 59
- Assignees
- 41
- Inventors
- 125
- Latest grant
- 14 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 2 | 0 |
| 1977 | 0 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 1 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 1 | 0 |
| 1998 | 1 | 0 |
| 1999 | 2 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 1 |
| 2004 | 0 | 2 |
| 2005 | 0 | 0 |
| 2006 | 0 | 1 |
| 2007 | 1 | 1 |
| 2008 | 0 | 1 |
| 2009 | 0 | 1 |
| 2010 | 0 | 1 |
| 2011 | 2 | 3 |
| 2012 | 0 | 2 |
| 2013 | 2 | 4 |
| 2014 | 2 | 3 |
| 2015 | 5 | 8 |
| 2016 | 3 | 2 |
| 2017 | 2 | 4 |
| 2018 | 4 | 5 |
| 2019 | 1 | 2 |
| 2020 | 0 | 4 |
| 2021 | 2 | 0 |
| 2022 | 1 | 2 |
| 2023 | 2 | 4 |
| 2024 | 1 | 5 |
| 2025 | 1 | 2 |
| 2026 | 3 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Pharmaceutical combinations comprising insulin and at least an agent selected from meloxicam, bromfenac sodium, acetylsalicylic acid, salicyclic acid and paracetamol14 Jul 2026US 12,678,490 B2Eli Lilly and Company
- Synergistic antibacterial activity of medium polarity oils in combination with antibacterial agents on bacterial biofilms31 Mar 2026US 12,588,675 B2Smith & Nephew, Inc.
- Pharmaceutical suspensions for bismuth subsalicylates17 Mar 2026US 12,576,092 B2L. Perrigo Company
- Pharmaceutical composition comprising tizoxanide and pharmaceutical use thereof5 Aug 2025US 12,378,210 B2Beijing Junke Huayuan Med Tech Co., Ltd.
- High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions2 Jan 2024US 11,857,545 B2Techfields Pharma Co., Ltd.
- Chewable compositions9 Jul 2026US 2026/0191774 A1Harmony Foods, Inc.
- Catalytic inhibitor of protein phosphatase 5 activates the extrinsic apoptotic pathway by disrupting complex ii27 Nov 2025US 2025/0360108 A1The Research Foundation for The State University of New York
- Prevention or treatment of cardiovascular diseases with high penetration prodrugs of aspirin and other nsaids27 Mar 2025US 2025/0099491 A1Techfields Inc.
- New combination drug for treating coronavirus infections, pharmaceutical composition and use thereof21 Nov 2024US 2024/0382510 A1
- High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions11 Jul 2024US 2024/0226084 A9Techfields Pharma Co., Ltd.
Most cited
By later US patents
- Treatment of non-inflammatory and non-infectious bowel disorders103US 5,519,014 A1996
- N-acyl anthranilic acid derivative or salt thereof32US 8,492,582 B2Toyama Chemical Co., Ltd. · 2013
- Zinc-based antiirritant creams24US 5,985,918 AThe Trustees of Columbia University in the City of New York · 1999
- Function regulator for retinoid relative receptor21US 7,223,791 B2Takeda Pharmaceutical Company Limited · 2007
- Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid17US 7,994,206 B2Janssen Pharmaceutica NV · 2011